Teva Highlights New Real-World Findings on AUSTEDO and AUSTEDO XR for Huntington’s Disease

PARSIPPANY, N.J. and TEL AVIV, Israel — June 5, 2026 — Teva Pharmaceutical Industries Ltd. has announced new data demonstrating that treatment with AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets may provide significant benefits for people living with Huntington’s disease (HD), particularly those experiencing chorea, a movement disorder characterized by involuntary and unpredictable body movements.

The newly presented findings reveal that patients treated with AUSTEDO and AUSTEDO XR reported noticeable improvements in symptom control, daily functioning, physical mobility, and overall quality of life. In addition, caregivers reported positive changes in patient independence and reduced caregiving burden, highlighting the broader impact of effective symptom management in Huntington’s disease.

Understanding Huntington’s Disease and Chorea

Huntington’s disease is a rare, inherited neurodegenerative disorder that progressively affects movement, cognition, and behavior. One of the most visible symptoms of the disease is chorea, which causes sudden, involuntary movements that can interfere with walking, eating, speaking, sleeping, and performing everyday tasks.

As the disease progresses, patients often experience increasing difficulty maintaining independence. Family members and caregivers frequently take on greater responsibilities, making treatment approaches that improve symptom control particularly important.

New Data Presented by Teva

According to Teva, the latest analyses focused on real-world patient experiences with AUSTEDO and AUSTEDO XR. The findings indicate that patients experienced improvements not only in movement symptoms but also in aspects of daily living that are directly affected by Huntington’s disease. These outcomes were measured through patient-reported and caregiver-reported assessments.

The company emphasized that the data provide valuable insight into how symptom management can influence broader quality-of-life outcomes beyond traditional clinical measurements.

Key Reported Benefits

• Improved control of involuntary chorea movements
• Enhanced ability to perform everyday physical activities
• Greater independence in daily routines
• Better overall mobility and movement control
• Positive impact on patient well-being and confidence
• Reduced caregiving burden reported by family members and caregivers

Patient Experiences Reflect Meaningful Progress

Many patients participating in real-world assessments reported that treatment helped them regain greater control over movements that had previously disrupted daily activities. Improvements in mobility may allow patients to perform tasks such as walking, climbing stairs, dressing, bathing, and carrying objects with greater ease. Similar benefits have been observed in previous studies evaluating deutetrabenazine treatment in Huntington’s disease chorea.

Researchers noted that even modest reductions in chorea symptoms can have a substantial impact on quality of life, helping individuals participate more fully in social activities and maintain greater independence.

Caregiver Feedback Highlights Broader Benefits

Caregivers play a critical role in supporting individuals with Huntington’s disease. The newly presented findings suggest that improvements in symptom management can positively affect caregivers as well as patients.

When patients experience better movement control and increased ability to perform routine activities independently, caregivers may spend less time assisting with physical tasks and daily supervision. This can reduce emotional and practical burdens while improving overall family well-being.

Teva stated that caregiver-reported outcomes are becoming increasingly important in evaluating treatment success because they provide additional insight into how therapies affect everyday life outside clinical settings.

AUSTEDO and AUSTEDO XR: Treatment Options for Huntington’s Disease Chorea

AUSTEDO and AUSTEDO XR contain the active ingredient deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of chorea associated with Huntington’s disease. The medication works by helping regulate neurotransmitter activity involved in abnormal involuntary movements.

AUSTEDO XR is a once-daily extended-release formulation designed to provide the same active ingredient while offering a simplified dosing schedule compared with the original twice-daily AUSTEDO formulation. Previous research has demonstrated therapeutic equivalence between the two formulations.

Advantages of AUSTEDO XR

• Once-daily administration
• Flexible dosing options
• Established efficacy in reducing chorea symptoms
• Potential to improve treatment adherence and convenience
• Real-world evidence supporting patient satisfaction

Importance of Real-World Evidence

While clinical trials remain essential for evaluating safety and efficacy, real-world evidence provides a broader understanding of how treatments perform in routine clinical practice. Patients enrolled in observational studies often represent more diverse populations than those included in controlled trials.

Teva emphasized that patient-reported outcomes offer valuable perspectives on treatment effectiveness, helping healthcare providers better understand how therapies influence daily functioning, emotional well-being, and long-term quality of life.

Expert Perspectives

Healthcare professionals specializing in movement disorders continue to emphasize the importance of addressing symptoms that directly affect patient independence and caregiver burden. Effective management of chorea can help patients remain active longer and participate more fully in family and community activities.

The latest findings presented by Teva support growing evidence that treatment benefits extend beyond symptom reduction alone, contributing to meaningful improvements in daily life.

The Growing Need for Improved Huntington’s Disease Care

Although Huntington’s disease remains a progressive condition without a cure, advances in symptom management continue to improve patient care. Researchers, clinicians, advocacy groups, and pharmaceutical companies are working to develop therapies that not only address motor symptoms but also improve overall quality of life.

The latest data presented by Teva reinforce the importance of listening to both patients and caregivers when evaluating treatment outcomes. Their experiences provide a more complete picture of how therapies influence life beyond traditional clinical measurements.

Looking Ahead

Teva indicated that it will continue evaluating real-world outcomes associated with AUSTEDO and AUSTEDO XR as part of its ongoing commitment to understanding the needs of people living with Huntington’s disease.

Future research is expected to further examine long-term treatment experiences, patient satisfaction, caregiver perspectives, and the broader impact of symptom control on daily functioning and independence.

As new evidence emerges, healthcare providers may gain additional insights into how AUSTEDO and AUSTEDO XR can support patients living with Huntington’s disease chorea and help improve quality of life for both patients and caregivers.

#HuntingtonsDisease #AUSTEDO #AUSTEDOXR #NeurologyNews #SlimScan #GrowthStocks #CANSLIM